Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors Jessica Jiyeong Lin, Enriqueta Felip, Byoung Chul Cho, Benjamin Besse, Geoffrey Liu, Lorenza Landi, Luis G. Paz-Ares, Chiara Bennati, Aurélie Swalduz, Sanjay Popat, Misako Nagasaka, Joshua E. Reuss, Christina S. Baik, Julien Mazieres, Melissa Lynne Johnson, Adrianus Johannes De Langen, Ji-Youn Han, Malinda Itchins, Viola Zhu, and Alexander E. Drilon
Title ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
URL https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.8503?referrer=https%3A%2F%2Fwww.google.com%2F
Abstract Text Background: Neladalkib is an investigational ALK TKI designed for inhibition of ALK single and compound resistance mutations, brain penetrance, and sparing TRK. We report the first analyses of phase 2 TKI pre-treated patients (pts) and preliminary data in TKI-naïve pts with ALK+ NSCLC. Methods: The global, single arm phase 1/2 ALKOVE-1 trial (NCT05384626) enrolled pts with advanced/metastatic ALK+ NSCLC. Key study endpoints are objective response rate (ORR, RECIST v1.1 by BICR), duration of response (DOR), intracranial ORR (IC-ORR) and safety. Efficacy analyses included TKI pre-treated pts who initiated neladalkib 150 mg QD by 30 Sep 2024 or all treated TKI-naïve pts. Data cut: 29 Aug 2025. Results: 656 pts with ALK+ NSCLC received neladalkib. Efficacy-evaluable TKI pre-treated pts (n=253) had received a median of 3 prior anticancer therapies (range 1-11, 51% prior chemo). 78% of pts received ≥2 (range 2-5) prior ALK TKIs, of whom 91% had prior lorlatinib. 19% had single or compound ALK G1202R resistance mutations. 40% had CNS disease by BICR. ALK TKI pre-treated results are reported in the Table. In a preliminary analysis of TKI-naïve pts, ORR was 86% (38/44, 2 uPRs); 12-month DOR rate was 91%. IC-ORR was 78% (7/9) with no CNS progression events as of data cutoff. Conclusions: In this ALK TKI pre-treated data set, neladalkib demonstrated clinically meaningful activity, including in pts with CNS disease, ALK G1202R single or compound mutations, and prior lorlatinib. Encouraging preliminary activity was also observed in TKI-naïve pts. Neladalkib’s safety profile was consistent with its ALK-selective, TRK-sparing design. Clinical trial information: NCT05384626.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK fusion lung non-small cell carcinoma sensitive Neladalkib FDA approved Actionable In a Phase I/II trial (ALKOVE-1) that supported FDA approval, Nelkarmi (neladalkib) treatment resulted in an objective response rate of 31% (79/253) in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 64% and over 18 mo in 53% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
ALK fusion ALK G1202R lung non-small cell carcinoma predicted - sensitive Neladalkib Phase Ib/II Actionable In a Phase I/II trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in an objective response rate of 68% (32/47) in patients with ALK-positive non-small cell lung cancer harboring ALK G1202R who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 80% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
ALK rearrange lung non-small cell carcinoma sensitive Neladalkib FDA approved Actionable In a Phase I/II trial (ALKOVE-1) that supported FDA approval, Nelkarmi (neladalkib) treatment resulted in an objective response rate of 31% (79/253) in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 64% and over 18 mo in 53% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...